Neulasta

Latest stories

1d
Channel NewsAsia
EU agency accepts Sandoz application for pegfilgrastim biosimilarZURICH: The European Medicines Agency (EMA) has accepted an application to revi
EU agency accepts Sandoz application for pegfilgrastim biosimilar
Channel NewsAsia / Posted yesterday
ZURICH: The European Medicines Agency (EMA) has accepted an application to review Sandoz's biosimilar to Amgen's EU-licensed Neulasta (pegfilgrastim), a recombinant human granulocyte colony-stimulating factor, Sandoz parent Novartis said on... Read more
7d
Pacific Coast Business Times
Amgen revenues up 8 percent in 2015Despite increased competition from biosimilars and blockbuster mergers by its r
Amgen revenues up 8 percent in 2015
Pacific Coast Business Times / Posted 7 days ago
Despite increased competition from biosimilars and blockbuster mergers by its rivals, Amgen revenues rose 8 percent to $21.67 billion in 2015 from $20.06 billion in 2014. Thousand Oaks-based biotech giant Amgen released its fourth-quarter earnings... Read more
8d
San Antonio Express-News
Will 2016 Be Amgen Inc.'s Best Year Yet?Image source: Amgen via Flickr. For shareholders, Amgen's 2015 seemed largely
Will 2016 Be Amgen Inc.'s Best Year Yet?
San Antonio Express-News / Posted 8 days ago
Image source: Amgen via Flickr. For shareholders, Amgen's 2015 seemed largely forgettable based solely on the movement of its stock. Amgen shares finished the year higher by a meager 2%. But when it comes to product and pipeline advancements, Amgen... Read more
3 related stories
12d
San Antonio Express-News
Where to Invest Money in 2016: 7 Great IdeasOn the heels of a historically painful start for the stock market this year, it
Where to Invest Money in 2016: 7 Great Ideas
San Antonio Express-News / Posted 12 days ago
On the heels of a historically painful start for the stock market this year, it might be tempting to stuff your cash into the nearest mattress and hope for the best. But even apart from the risk of inflation eating away at the value of your mattress'... Read more
13d
San Antonio Express-News
Amgen's Q4 Crushed Estimates and Answered 3 Important Questions in the ProcessImage source: Amgen via Flickr. Amgen , the original blue-chip biotech company
Amgen's Q4 Crushed Estimates and Answered 3 Important Questions in the Process
San Antonio Express-News / Posted 13 days ago
Image source: Amgen via Flickr. Amgen , the original blue-chip biotech company, reported its highly anticipated fourth-quarter earnings results after the closing bell last night -- and surprise, surprise, they didn't disappoint. Amgen crushes Wall... Read more
14d
The Tampa Tribune
Amgen trounces Street views with 39 pct. jump in 4Q profitTRENTON, N.J. (AP) � Capping an enviable year, Amgen's fourth-quarter profit so
Amgen trounces Street views with 39 pct. jump in 4Q profit
The Tampa Tribune / Posted 14 days ago
TRENTON, N.J. (AP) � Capping an enviable year, Amgen's fourth-quarter profit soared 39 percent, as the biologic drugmaker posted higher revenue for nearly all its medicines. The company's results trounced analyst expectations for the fifth-straight... Read more
4 related stories
14d
The Record Searchlight
Amgen trounces Street views with 39 pct. jump in 4Q profitTRENTON, N.J. (AP) - Capping an enviable year, Amgen's fourth-quarter profit so
Amgen trounces Street views with 39 pct. jump in 4Q profit
The Record Searchlight / Posted 14 days ago
TRENTON, N.J. (AP) - Capping an enviable year, Amgen's fourth-quarter profit soared 39 percent, as the biologic drugmaker posted higher revenue for nearly all its medicines. The company's results trounced analyst expectations for the fifth-straight... Read more
4 related stories
14d
Chattanooga Times Free Press
Amgen trounces Street views with 39 pct. jump in 4Q profitTHOUSAND OAKS, Calif. (AP) - Amgen's fourth-quarter profit soared 39 percent, a
Amgen trounces Street views with 39 pct. jump in 4Q profit
Chattanooga Times Free Press / Posted 14 days ago
THOUSAND OAKS, Calif. (AP) - Amgen's fourth-quarter profit soared 39 percent, as the biologic drugmaker posted higher revenue for nearly all its medicines and trounced analyst expectations for the fifth straight quarter. The world's biggest biotech... Read more
4 related stories
14d
Market Watch
Amgen profit rises 39%; 2016 outlook raisedAmgen Inc. said its fourth-quarter earnings rose 39% as revenue benefited from
Amgen profit rises 39%; 2016 outlook raised
Market Watch / Posted 14 days ago
Amgen Inc. said its fourth-quarter earnings rose 39% as revenue benefited from higher prices and strong sales of Enbrel, Kyprolis and the biotechnology company's osteoporosis drugs. Per-share earnings, excluding certain one-time items, and revenue... Read more
14 related stories
14d
Daily Herald
Amgen trounces Street views with 39 pct. jump in 4Q profitTHOUSAND OAKS, Calif. -- Amgen's fourth-quarter profit soared 39 percent, as th
Amgen trounces Street views with 39 pct. jump in 4Q profit
Daily Herald / Posted 14 days ago
THOUSAND OAKS, Calif. -- Amgen's fourth-quarter profit soared 39 percent, as the biologic drugmaker posted higher revenue for nearly all its medicines and trounced analyst expectations for the fifth straight quarter. The world's biggest biotech... Read more
4 related stories
14d
Reuters
Amgen 4th quarter profit tops street; raises 2016 forecastAn Amgen sign is seen at the company's office in South San Francisco, Californi
Amgen 4th quarter profit tops street; raises 2016 forecast
Reuters / Posted 14 days ago
An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. Amgen Inc (AMGN.O) on Thursday reported much higher-than-expected fourth-quarter earnings, helped by increased sales of its blockbuster rheumatoid... Read more
22d
News-Medical-Net
UM SOM study leads to FDA approval of Neulasta drug for treatment of radiation injuryAs a result of research performed by scientists at the University of Maryland S
UM SOM study leads to FDA approval of Neulasta drug for treatment of radiation injury
News-Medical-Net / Posted 22 days ago
As a result of research performed by scientists at the University of Maryland School of Medicine (UM SOM), the U.S. Food and Drug Administration (FDA) has approved the use of a drug to treat the deleterious effects of radiation exposure following a... Read more
1m
Channel NewsAsia
Baxalta-Coherus Enbrel biosimilar succeeds in late-stage studyREUTERS: Baxalta Inc and Coherus Biosciences Inc said their experimental biosim
Baxalta-Coherus Enbrel biosimilar succeeds in late-stage study
Channel NewsAsia / Posted a month ago
REUTERS: Baxalta Inc and Coherus Biosciences Inc said their experimental biosimilar of Amgen Inc's arthritis drug Enbrel met the main goal in a late-stage study. The drug, CHS-0214, was found to be as effective as Enbrel in rheumatoid arthritis... Read more

People in this news